TABLE 2.
Effect of inhibitory activity of rabbit anti-N63 IgG in the absence or presence of enfuvirtide on infection by primary HIV-1 isolatesa
| Inhibitor A | CI | IC50 (nM) |
Dose reduction (fold) | Inhibitor B | IC50 (nM) |
Dose reduction (fold) | ||
|---|---|---|---|---|---|---|---|---|
| Alone | In mixture | Alone | In mixture | |||||
| 92UG029 (subtype A, X4) | ||||||||
| Enfuvirtide | 0.26 ± 0.02 | 16.29 ± 0.82 | 4.13 ± 0.41 | 2.94 | Anti-N63 IgG | >3,000 | 82.69 ± 8.27 | >35.28 |
| 94US_33931N (subtype B, R5) | ||||||||
| Enfuvirtide | 0.20 ± 0.01 | 25.44 ± 1.82 | 4.82 ± 0.47 | 4.28 | Anti-N63 IgG | >3,000 | 96.25 ± 9.48 | >30.17 |
| 93IN101 (subtype C, R5) | ||||||||
| Enfuvirtide | 0.15 ± 0.01 | 20.60 ± 2.68 | 2.91 ± 0.17 | 6.08 | Anti-N63 IgG | >3,000 | 58.09 ± 3.39 | >50.64 |
| 92UG024 (subtype D, X4) | ||||||||
| Enfuvirtide | 0.20 ± 0.01 | 12.61 ± 2.06 | 2.45 ± 0.54 | 4.15 | Anti-N63 IgG | >3,000 | 48.97 ± 10.75 | >60.26 |
| 92TH009 (subtype A/E, R5) | ||||||||
| Enfuvirtide | 0.19 ± 0.02 | 24.14 ± 2.43 | 4.16 ± 0.08 | 4.80 | Anti-N63 IgG | >3,000 | 83.21 ± 1.73 | >35.05 |
| 93/BR/020 (subtype F, X4 and R5) | ||||||||
| Enfuvirtide | 0.18 ± 0.02 | 17.14 ± 2.18 | 2.99 ± 0.73 | 4.73 | Anti-N63 IgG | >3,000 | 59.78 ± 14.58 | >49.18 |
| BCF02 (group O, R5) | ||||||||
| Enfuvirtide | 0.14 ± 0.01 | 42.69 ± 3.34 | 5.18 ± 0.18 | 7.24 | Anti-N63 IgG | >3,000 | 103.48 ± 3.50 | >27.99 |
a
The inhibitory activity of enfuvirtide and anti-N63 IgG purified from sera of rabbits immunized with N63, alone or in combination, on infection by primary HIV-1 isolates in CEMx174 5.25M7 cells using p24 assay as described above. All HIV-1 strains were obtained from the NIH AIDS Research and Reference Reagent Program. Each sample was tested in triplicate. The experiments were repeated three times, and the data are presented as means ± SD. The average variability between the results of the repeated experiments was about 9%.